The programmed death‐ligand 1 (PD‐L1) and PD‐1 inhibitor have shown prolonged response as either monotherapy or in combination with cytotoxic chemotherapy in non‐small cell lung cancer (NSCLC), and adenocarcinoma.1, 2. Here, PDCD1 is linked to non-small cell lung carcinoma.